Molecular targeting and gene delivery in bladder cancer therapy

Journal of B.U.ON.

Volumn 14, Issue SUPPL.1, 2009, Pages

  Voutsinas, Gerassimos E ^a   Stravopodis, D J ^b  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Bladder cancer; Gene therapy; Targeted therapy

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 [1 (3 FLUOROBENZYL) 5 INDAZOLYLAMINO] 5 METHYLPYRROLO[2,1 F][1,2,4]TRIAZINE 6 CARBAMIC ACID 3 MORPHOLINOMETHYL ESTER; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BORTEZOMIB; CETUXIMAB; DEFOROLIMUS; ERLOTINIB; EVEROLIMUS; FLAVOPIRIDOL; GEFITINIB; LONAFARNIB; MATUZUMAB; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NOVOBIOCIN; PANITUMUMAB; PELITINIB; PERTUZUMAB; R 11577; RADICICOL; RAPAMYCIN; SORAFENIB; SUNITINIB; TANESPIMYCIN; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

ANGIOGENESIS; APOPTOSIS; BLADDER CANCER; CANCER GENE THERAPY; CANCER INVASION; CELL CYCLE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXICITY; DNA METHYLATION; GENE TARGETING; HUMAN; IMMUNOMODULATION; METASTASIS; NONHUMAN; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; APOPTOSIS; ENDOSTATINS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70350042935     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (73)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, version 1.0. IARC Cancer Base No.5, Lyon: IARC Press; 2001.
2. Clark PE. Bladder cancer. Curr Opin Oncol 2007; 19: 241-247.
3. Mhawech-Fauceglia P, Cheney RT, Schwaller J. Genetic alterations in urothelial bladder carcinoma: an updated review. Cancer 2006; 106: 1205-1216. (Pubitemid 43363896)
4. Wallerand H, Reiter RR, Ravaud A. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signaling pathways Curr Opin Urol 2008; 18: 524-532.
5. Black PC, Agarwal PK, Dinney CPN. Targeted therapies in bladder cancer - an update. Urol Oncol 2007; 25: 433-438. (Pubitemid 47362765)
6. Black PC, Brown GA, Dinney CP. The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol 2009; 27: 3-7.
7. Bochner BH. Gene therapy in bladder cancer. Curr Op Urol 2008; 18: 519-523.
8. Tyagi P, Wu PC, Chancellor M, Yoshimura N, Huang L. Recent advances in intravesical drug/gene delivery. Mol Pharm 2006; 3: 369-379. (Pubitemid 44351919)
9. Hendricksen K, Witjes JA. Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer. Curr Opin Urol 2007; 17: 352-357. (Pubitemid 47351133)
10. Lopez-Bertran A, Luque RJ, Mazzucchelli R, Scarpelli M, Montironi R. Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer. J Clin Pathol 2002; 55: 641-647. (Pubitemid 34970083)
11. Shen Z, Shen T, Wientjes MG, O'Donnel MA, Au JL-S. Intravesical treatments of bladder cancer: Review. Pharm Res 2008; 25: 1500-1510.
12. Alonzi R, Hoskin P. Novel therapies in bladder cancer. Clin Oncol 2005; 17: 524-538.
13. Schultz WA. Understanding urothelial carcinoma through cancer pathways. Int J Cancer 2006; 119: 1513-1518.
14. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005; 5: 713-725.
15. Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 2007; 21: 3214-3231. (Pubitemid 350277749)
16. Rosa DD, Ismael G, Lago LD, Awada A. Molecularly-targeted therapies: Lessons from years of clinical development. Cancer Treat Rev 2008; 34: 61-80. (Pubitemid 351168606)
17. Kassouf W, Dinney CP, Brown G et al. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res 2005; 65: 10524-10535. (Pubitemid 41748146)
18. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537. (Pubitemid 41540110)
19. Villares GJ, Zigler M, Blehm K et al. Targeting EGFR in bladder cancer. World J Urol 2007; 25: 573-579.
20. Kassouf W, Luongo T, Brown G, Adam L, Dinney CP. Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. J Urol 2006; 176: 787-792. (Pubitemid 43927919)
21. Krüger S, Weitsch G, Büttner H et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer 2002; 102: 514-518. (Pubitemid 35316007)
22. Hussain MH, McVicar GR, Petrylak DP et al; National Cancer Institute. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007; 25: 2218-2224. (Pubitemid 46954646)
23. Roberts WG, Whalen PM, Soderstrom E et al. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res 2005; 65: 957-966. (Pubitemid 40216457)
24. Kane RC, Farrell AT, Saber H et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006; 12: 7271-7278. (Pubitemid 46095398)
25. Kapoor A, Gharajeh A, Sheikh A, Pinthus J. Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma. Curr Oncol 2009; 16(Suppl 1): S60-66.
26. Bradley DA, Dunn R, Nanus D et al. Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. Clin Genitourin Cancer 2007; 5: 460-463. (Pubitemid 351219702)
27. Dinney CP, McConkey DJ, Millikan RE et al. Focus on bladder cancer. Cancer Cell 2004; 6: 111-116.
28. Buyru N, Tigli H, Ozcan F, Dalay N. Ras oncogene mutations in urine sediments of patients with bladder cancer. J Biochem Mol Biol 2003; 36: 399-402. (Pubitemid 37100932)
29. Winquist E, Moore MJ, Chi KN et al. A multinomial phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol Oncol 2005; 23: 143-149. (Pubitemid 40720377)
30. Rosenberg JE, von der Maase H, Seigne JD et al. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer 2005; 103: 2035-2041.
31. Kinkade CW, Castillo-Martin M, Puzio-Kuter A et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008; 118: 3051-3064.
32. Engelman JA, Chen L, Tan X et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14: 1351-1356.
33. Mahoney CL, Choudhury B, Davies H et al. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. Br J Cancer 2009; 100: 370-375.
34. Fechner G, Classen K, Schmidt D, Hauser S, Móller SC. Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer. Urology 2009; 73: 665-668.
35. Stravopodis DJ, Margaritis LH, Voutsinas GE. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex. Curr Med Chem 2007; 14: 3122-3138.
36. Sos ML, Michel K, Zander T et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 2009; 119: 1727-1740.
37. Mitsiades CS, Hideshima T, Chauhan D et al. Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol 2009; 46: 166-175.
38. Christoph F, Kempkensteffen C, Weikert S et al. Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. Br J Cancer 2006; 95: 1701-1707. (Pubitemid 44950797)
39. Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 2007; 74: 659-671.
40. Zhu WG, Otterson GA. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents 2003; 3: 187-199.
41. Schraml P, Bucher C, Bissig H et al. Cyclin E overexpression and amplification in human tumours. J Pathol 2003; 200: 375-382. (Pubitemid 36827312)
42. Senderowicz AM. Inhibitors of cyclin-dependent kinase modulators for cancer therapy. Prog Drug Res 2005; 63: 183-206.
43. Hunt T. You never know: Cdk inhibitors as anti-cancer drugs. Cell Cycle 2008; 7: 3789-3790.
44. Rao CV, Swamy MV, Patlolla JM, Kopelovich L. Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APCmin/+ mice. Cancer Res 2008; 68: 7670-7675.
45. Lambert JM, Gorzov P, Veprintsev DB et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 2009; 15: 376-388.
46. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899-1911. (Pubitemid 29407357)
47. Reed JC. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 1995; 9: 451-473.
48. Chanan-Khan AA, Niesvizky R, Hohl RJ et al. Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leuk Lymphoma 2009; 50: 559-565.
49. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 2003; 29 (Suppl 1): 3-9. (Pubitemid 36626287)
50. Papageorgiou A, Kamat A, Benedict WF, Dinney C, McConkey DJ. Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther 2006; 5: 3032-3041.
51. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000; 52: 237-268. (Pubitemid 30368433)
52. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2: 795-803. (Pubitemid 37328914)
53. Aotake T, Lu CD, Chiba Y, Muraoka R, Tanigawa N. Changes of angiogenesis and tumor cell apoptosis during colorectal carcinogenesis. Clin Cancer Res 1999; 5: 135-142. (Pubitemid 29045186)
54. Elfiky AA, Rosenberg JE. Targeting angiogenesis in bladder cancer. Curr Oncol Rep 2009; 11: 244-249.
55. Agarwal N, Hussain M. Management of bladder cancer: current and emerging strategies. Drugs 2009; 69: 1173-1187.
56. Määttä M, Santala M, Soini Y, Talvensaari-Mattila A, Turpeenniemi-Hujanen T Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low malignant potential ovarian tumors. Tumour Biol 2004; 25: 188-192. (Pubitemid 39551745)
57. Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004; 10: 7621-7628.
58. Butler GS, Overall CM. Proteomic validation of protease drug targets: pharmacoproteomics of matrix metalloproteinase inhibitor drugs using isotope-coded affinity tag labelling and tandem mass spectrometry. Curr Pharm Des 2007; 13: 263-270.
59. Heath EI, Burtness BA, Kleinberg L et al. Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Invest New Drugs 2006; 24: 135-140. (Pubitemid 43723905)
60. Hatefi A, Canine BF. Perspectives in vector development for systemic cancer gene therapy. Gene Ther Mol Biol 2009; 13: 15-19.
61. Dorer DE, Nettelbeck DM. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv Drug Deliv Rev 2009; 61: 554-571.
62. Tao Z, Connor RJ, Ashoori F et al. Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation. Cancer Gene Ther 2006; 13: 125-130. (Pubitemid 43113413)
63. Loskog AS, Fransson ME, Totterman TT. AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model. Clin Cancer Res 2005; 11: 8816-8821.
64. Kikuchi E, Menendez S, Ohori M, Cordon-Cardo C, Kasahara N, Bochner BH. Inhibition of orthotopic human bladder tumor growth by lentiviral gene transfer of endostatin. Clin Cancer Res 2004; 10: 1835-1842. (Pubitemid 38435575)
65. Inoue K, Perrotte P, Wood CG, Slaton JW, Sweeney P, Dinney CP. Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor. Clin Cancer Res 2000; 6: 4422-4431. (Pubitemid 30840198)
66. Shieh GS, Shiau AL, Yo YT et al. Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model. Cancer Res 2006; 66: 9957-9966.
67. Wada Y, Gotoh A, Shirakawa T, Hamada K, Kamidono S. Gene therapy for bladder cancer using adenoviral vector. Mol Urol 2001; 5: 47-52. (Pubitemid 32448695)
68. Irie A, Matsumoto K, Anderegg B et al. Growth inhibition efficacy of an adenovirus expressing dual therapeutic genes, wild-type p53, and anti-erbB2 ribozyme, against human bladder cancer cells. Cancer Gene Ther 2006; 13: 298-305. (Pubitemid 43255767)
69. Ruifa H, Liwei L, Binxin L, Ximing L. Additional gene therapy with rAAV-wt-p53 enhanced the efficacy of cisplatin in human bladder cancer cells. Urol Int 2006; 77: 355-361. (Pubitemid 44837006)
70. Inoue M, Tomizawa K, Matsushita M et al. p53 protein transduction therapy: successful targeting and inhibition of the growth of the bladder cancer cells. Eur Urol 2006; 49: 161-168. (Pubitemid 41789974)
71. Horowitz JM, Park SH, Bogenmann E et al. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci U S A 1990; 87: 2775-2779. (Pubitemid 20141822)
72. Wadayama B, Toguchida J, Shimizu T et al. Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res 1994; 54: 3042-3048. (Pubitemid 24187793)
73. Zhang X, Multani AS, Zhou JH et al. Adenoviral-mediated retinoblastoma 94 produces rapid telomere erosion, chromosomal crisis, and caspase-dependent apoptosis in bladder cancer and immortalized human urothelial cells but not in normal urothelial cells. Cancer Res 2003; 63: 760-765. (Pubitemid 36231972)